and supplementation of ursodeoxycholic acid (UDCA) could ameliorate statin-induced glucose intolerance
10.12688/f1000research.20602.1 61 RichardJ
Future studies of the medicine could then focus on the right people, improving chances of success. In the longer term, our work could help people with Parkinsons live well for longer and could save the NHS money by avoiding treatments that do not help. Dr Cynthia Sandor from Imperial College London is the Principal Investigator of this study and is funded by the UK Dementia Research Institute, the Safra Foundation and the Michael J
Short-term GLP-1 use usually refers to taking the medication for 812 weeks, or up to 36 months, rather than as ongoing treatment
Furthermore, manufacturers may have been aware that gastroparesis and other serious side effects were possible
For more information, visit Ostrophin PMG Ostrophin PMG contains veal bone PMG extract, a proprietary Protomorphogen blend